missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Human L-Selectin/CD62L Antibody, R&D Systems™
Mouse Monoclonal Antibody has been used in 7 publications
Brand: R&D Systems BBA24
This item is not returnable.
View return policy
Description
L-Selectin/CD62L Monoclonal specifically detects L-Selectin/CD62L in Human samples. It is validated for Flow Cytometry, CyTOF-ready, ELISA Capture (Matched Antibody Pair).
Specifications
| L-Selectin/CD62L | |
| Monoclonal | |
| LYOPH | |
| Flow Cytometry 2.5 ug/10^6 cells, CyTOF-ready, ELISA Capture (Matched Antibody Pair) 2-8 ug/mL | |
| CD62L, CD62L antigen, gp90-MEL, hLHRc, LAM1, LAM-1, LAM1LECAM1, LECAM1, Leu-8, LEU8, Leukocyte adhesion molecule 1, Leukocyte surface antigen Leu-8, Leukocyte-endothelial cell adhesion molecule 1, LNHR, LNHRTQ1, LSEL, L-selectin, Lyam-1, LYAM1, LYAM1CD62 antigen-like family member L, Lymph node homing receptor, lymphocyte adhesion molecule 1, pln homing receptor, PLNHR, selectin L, SELL, TQ1 | |
| Mouse | |
| Protein A or G purified from hybridoma culture supernatant | |
| RUO | |
| 6402 | |
| Sterile PBS to a final concentration of 0.5 mg/mL. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
| IgG1 |
| Flow Cytometry, CyTOF, ELISA | |
| 4G8 | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. with No Preservative | |
| SELL | |
| Recombinant human L-Selectin/CD62L Extracellular domain | |
| 200 μg | |
| Primary | |
| Binds to CHO cells expressing the human L-Selectin/CD62L protein. It does not recognize CHO cells expressing either the human E-Selectin or human P-Selectin. | |
| Human | |
| Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction